This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ando, S.-i. Articles by Floras, J. S. Search for Related Content PubMed PubMed Citation Articles by Ando, S.-i. Articles by Floras, J. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Hazardous Substances DB SODIUM CHLORIDE

(Hypertension. 1995;26:1160-1166.)
© 1995 American Heart Association, Inc.

Articles

Comparison of Candoxatril and Atrial Natriuretic Factor in Healthy Men

Effects on Hemodynamics, Sympathetic Activity, Heart Rate Variability, and Endothelin

Shin-ichi Ando; Mohammed A. Rahman; Gary C. Butler; Beverley L. Senn; John S. Floras

From the Division of Cardiology, Toronto Hospital, and Centre for Cardiovascular Research, University of Toronto (Ontario, Canada).

Abstract The purpose of these experiments was to compare the effects of endopeptidase inhibition with oral candoxatril on systemic and forearm hemodynamics and muscle sympathetic nerve activity with responses to a low-dose atrial natriuretic factor infusion. Eleven healthy men received at random on three separate days either intravenous saline, atrial natriuretic factor (1.6 pmol/kg per minute) plus saline, or oral candoxatril (200 mg) plus saline. Measurements were made at baseline and 30, 60, and 90 minutes after interventions. Atrial natriuretic factor lowered diastolic pressure (P<.01), central venous pressure (P<.001), forearm blood flow (P<.05), and forearm vascular compliance (P<.05) but had no effect on systolic pressure, heart rate or its variability, stroke volume, sympathetic nerve activity, plasma norepinephrine, or endothelin-1. Plasma epinephrine increased (P<.01). Candoxatril lowered central venous pressure (P<.001) and increased systolic pressure (from 116±6 to 120±7 mm Hg; P<.05), endothelin (from 4.6±1.1 to 6.8±3.2 pmol/L; P<.02), and epinephrine (P<.05), without affecting any other variables. Candoxatril and atrial natriuretic factor lowered central venous pressure in healthy men without causing a reflex increase in sympathetic nerve activity or norepinephrine, yet epinephrine rose. This suggests that both interventions may specifically inhibit sympathetic nerve traffic to muscle at physiological plasma atrial natriuretic factor concentrations. However, whereas the peptide lowered blood pressure, candoxatril increased systolic pressure. These contrasting hemodynamic responses may be related to differences in plasma atrial natriuretic peptide concentration and to altered endothelin metabolism by candoxatril.

Key Words: blood pressure • catecholamines • cardiac output • endothelin • natriuretic peptide • nervous system • vascular resistance

This article has been cited by other articles:

				G. Sansoe, M. Aragno, R. Mastrocola, J. C. Cutrin, S. Silvano, G. Mengozzi, A. Smedile, F. Rosina, O. Danni, and M. Rizzetto Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1337 - F1343. [Abstract] [Full Text] [PDF]

				S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]

				A. C. Rosenkranz, S. G. Hood, R. L. Woods, G. J. Dusting, and R. H. Ritchie B-Type Natriuretic Peptide Prevents Acute Hypertrophic Responses in the Diabetic Rat Heart: Importance of Cyclic GMP Diabetes, September 1, 2003; 52(9): 2389 - 2395. [Abstract] [Full Text] [PDF]

				D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]

				Pacific Study Group and B. Neal Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 270 - 276. [Abstract] [PDF]

				F. Piquard, R. Richard, A. Charloux, S. Doutreleau, T. Hannedouche, G. Brandenberger, and B. Geny Hormonal, renal, hemodynamic responses to acute neutral endopeptidase inhibition in heart transplant patients J Appl Physiol, August 1, 2002; 93(2): 569 - 575. [Abstract] [Full Text] [PDF]

				G. A Sagnella Review: Vasopeptidase inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 90 - 95. [Abstract] [PDF]

				R. Corti, J. C. Burnett Jr, J. L. Rouleau, F. Ruschitzka, and T. F. Luscher Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? Circulation, October 9, 2001; 104(15): 1856 - 1862. [Abstract] [Full Text] [PDF]

				M. C. Petrie, C. Hillier, F. Johnston, and J. J.V. McMurray Effect of Neutral Endopeptidase Inhibition on the Actions of Adrenomedullin and Endothelin-1 in Resistance Arteries From Patients With Chronic Heart Failure Hypertension, September 1, 2001; 38(3): 412 - 416. [Abstract] [Full Text] [PDF]

				G. A. Sagnella Atrial natriuretic peptide mimetics and vasopeptidase inhibitors Cardiovasc Res, August 15, 2001; 51(3): 416 - 428. [Abstract] [Full Text] [PDF]

				H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]

				C. J. Ferro, J. C. Spratt, W. G. Haynes, and D. J. Webb Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo Circulation, June 16, 1998; 97(23): 2323 - 2330. [Abstract] [Full Text] [PDF]